This site complies with the HONcode standard for trustworthy health information: verify here.
Oncology Clinical News
Novartis to Buy Cancer-Drug Maker Endocyte for $2.1 Billion
A Year Early, Merck Touts Good Kidney Cancer News to Push Rival BMS
(Xconomy New York) Oct 18, 2018 - Merck could soon join rival Bristol-Myers Squibb in making immunotherapy an option for kidney cancer patients who have never had treatment before. Merck reported today that its blockbuster pembrolizumab (Keytruda) has hit its marks much earlier than expected in an 861-person Phase 3 study called Keynote-426. Merck tested a combination of pembrolizumab and axitinib (Inlyta), an approved kidney cancer drug from Pfizer, comparing it with sunitinib (Sutent), another approved drug that works in similar fashion to axitinib.
Read full article.
This site complies with the HONcode standard for trustworthy health information: verify here.